Ortho-mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

Other

Johnson & Johnson Pharmaceutical Research & Development, LLC

Xiaobing Li

Nicholas I Carruthers

William V Murray

J Guy Breitenbucher

Laura C McAtee

Ronald L Wolin

Cynthia Anne Maryanoff

Frank John Villani, Jr

Chandravadan R Shah

Timothy W Lovenberg

Allen B Reitz

Linda K Jolliffe

Virginia L Pulito

Linda Mulcahy

Gee-Hong Kuo

Dale A Rudolph

Haripada Khatuya

Catherine P Prouty

Richard H Hutchings

Nelson C F Yim

Todd Kevin Jones

Scott L Dax

Mark Andrew Youngman

Wenying Chai

Jill A Jablonowski

Mark Seierstad

Victor K Phuong

Steven W Sutton

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

Non-peptidic NPY Y2 receptor inhibitors

The invention features pharmaceutically-active imidazopyridines and derivatives that are substituted with phenyl, methods of making them, and methods of using them.

Phenyl-substituted imidazopyridines

In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections, are provided. In another aspect of the invention, methods are provided for the inhibition of Type III protein secretion and/or the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections using the compounds of the invention.

Pyridone compounds as inhibitors of bacterial type III protein secreation systems

Urea-containing, substituted 4-phenyl-[1,3]-dioxanes, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, obesity or a sleep/wake disorder mediated by orexin-2 are described.

Substituted 4-phenyl-[1,3]-dioxanes

This invention relates to a series of arylsubstituted piperazines, of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &#x3b1;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia

This invention relates a to a series of heterocyclic substituted piperazines of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &#x3b1;-adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

Heterocycles useful in the treatment of benign prostatic hyperplasia

The invention features methods of using pharmaceutically-active 2- or 3-aryl substituted imidazopyridines for the treatment of histamine H receptor-mediated disorders.

Method for treating histamine H3 receptor-mediated disorders with 2-  or 3-aryl substituted imidazo&lsqb;1,2-a&rsqb; pyridines

The invention features methods of using pharmaceutically-active 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzthiazoles and derivatives.

Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists

This invention relates to a series of arylsubstituted piperazines, of Formula I ##STR1## pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the .alpha.-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

Arylsubstituted piperazines useful in the treatment of benign prostatic

Growing community of inventors

San Diego, CA, United States of America

Xiaobing Li